Dalpiciclib plus cetuximab for certain head and neck cancers
Treatments studied
Part of Cancer clinical trials.
This trial tests a new combination of two drugs (dalpiciclib and cetuximab) versus cetuximab alone for people with head and neck cancer that is HPV-negative, has not responded to prior immunotherapy, and is not curable with surgery. The goal is to see if the combination works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your head and neck cancer has come back or spread, cannot be surgically removed, and is not caused by HPV.
- You have already tried a PD-1 immunotherapy (like Keytruda or Opdivo) and it stopped working, and it's been at least 4 weeks since your last dose.
- You have not been treated with cetuximab or similar EGFR-targeted drugs before.
- You are in generally good health (ECOG score 0 or 1) with adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two medications—cetuximab (a targeted antibody) and either pembrolizumab or finotonlimab (immunotherapies)—along with chemotherapy, for advanced head and neck cancer that has spread or come back. The goal is to see if this combination helps shrink tumors and improve survival compared to standard treatment.
This trial tests a new combination of two drugs (one targeted therapy and one immunotherapy) plus standard chemotherapy before surgery for head and neck cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests whether adding the drug dalpiciclib to standard hormone therapy improves outcomes for people with a certain type of early breast cancer (hormone receptor-positive, HER2-negative). It may help lower the risk of the cancer coming back.
This trial studies whether adding palbociclib to cetuximab works better than cetuximab by itself for head and neck cancer that is growing again after an anti–PD-1/PD-L1 treatment. It is for people whose tumor has a specific gene change (CDKN2A loss) and who have not had too many prior treatments.
This study tests a combination of two experimental drugs (adebrelimab and dalpiciclib) with standard chemotherapy given before surgery for head and neck cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for patients whose cancer is locally advanced but still removable.
This trial tests a new combination of two investigational drugs (adebrelimab and dalpiciclib) given before surgery for locally advanced head and neck cancer that is not linked to HPV. The goal is to see if these drugs can shrink the tumor and possibly improve outcomes.
Hear when a new Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.